Soledad Gomez Gonzalez
The researcher has a degree in Biotechnology since 2011 and a master's degree in Administration and Management of Biotechnological Companies.
In 2013, she obtained the Master in Biochemistry, Molecular Biology and Biomedicine at the Autonomous University of Barcelona.
In 2017, she obtained the title of doctor. Thesis "Developmental tumors, epigenetics and miRNAs" at the University of Barcelona.
In 2011, she did a stay in the Laboratory of Virology and Molecular Genetics at Tufts University in Boston, under the direction of Dr. John Coffin. And in 2015 the Biomedical Epigenomics Laboratory of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) in Barcelona carried out a stay, under the direction of Dr. José Ignacio Martín Subero.
Since 2020 she has been part of the Faculty of Doctors of the University of Barcelona.
She is currently working as a postdoctoral researcher in the Translational Genomics research group under the direction of Dr. Cinzia Lavarino (Principal Investigator) within the Developmental Tumors Laboratory, included in the IRSJD Pediatric Cancer Program. Her research line is focused on Bioinformatics and Big Data analysis for the identification of biomarkers and the development of classifiers that can be quickly transferred to clinical practice.
She currently leads the Design, Analysis and Interpretation of Data -OMICS (DAI-Omics) Unit of the Sant Joan de Déu Foundation, which provides service to research groups.
- Gonçalves-Alves EC, Garcia-López M, Gomez-Gonzalez S, Ecker RC, Suñol M, Muñoz-Aznar O, Carcaboso AM, Mora J, Lavarino C and Mateo-Lozano S AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(8): 4323.
- Pascual-Pastó G, Castillo H, Unceta N, Aschero MR, Resa-Parés C, Gómez-Caballero A, Vilà-Ubach M, Muñoz-Aznar O, Suñol M, Burgeño-Sandoval V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J and Carcaboso AM SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. JOURNAL OF CONTROLLED RELEASE . 342: 81-92.
- Aschero R, Francis JH, Ganiewich D, Gomez-Gonzalez S, Sampor C, Zugbi S, Ottaviani D, Lemelle L, Mena M, Winter U, Correa Llano G, Lamas G, Lubieniecki F, Szijan I, Mora J, Podhajcer O, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lavarino C and Chantada G Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers . 13(4): 673.
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.